InnaVirVax, a France-based specialist in the research and development of immuno-therapeutics for HIV, and Finland’s FIT Biotech (FITBIO:FN Finland) have announced an alliance in HIV.
The collaboration combines their respective proprietary immunotherapies, InnaVirVax’ VAC-3S and FIT Biotech’s FIT-06, which consist of vaccines with different mechanisms of action.
"Key opinion leaders have the vision that functional cure will be addressed by combining therapeutic approaches"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze